<unk>  may lower resistance to infections and should not be administered to patients with severe infections.<unk>  should be discontinued in patients with severe infusion related reactions, anaphylaxis, severe allergic reactions or cytokine release syndromes. Live vaccines should not be administered to patients receiving<unk>  since IL-6 inhibition may interfere with normal immune response to new antigens. Common The following has been shown to occur in treatment of Multicentric Castleman's disease with<unk>  during a clinical trial (>10% compared to placebo): * Peripheral edema * Abdominal Pain * Pruritus * Increased weight * Rash * Hyperuricemia * Upper respiratory tract infections Long term exposure * Upper respiratory tract infection * Pain in extremities * Arthralgia * Fatigue
Siltuximab
Dinutuximab
Margetuximab
Isatuximab
Loncastuximab tesirine
Alirocumab
Blinatumomab
Daratumumab